FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anas Younes

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Nicolas Batty; Luis Fayad; Lei Feng; Elham Ghonimi; Larry W Kwak; Peter McLaughlin; Maria Alma Rodriguez; Jorge Enrique Romaguera; Felipe Samaniego; Anas Younes; Fredrick B Hagemeister
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
Anas Younes; Amanda Copeland; Silvana de Castro Faria; Kantharaj Ethirajulu; Michelle A Fanale; Fredrick Hagemeister; Stefan Hart; Ramesh Jayaraman; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Jorge Romaguera; Jatin Shah; Jeanette Wood; Joy Zhu
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Anas Younes; Donald A Berry
From drug discovery to biomarker-driven clinical trials in lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anas Younes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nicolas Batty; Luis Fayad; Lei Feng; Elham Ghonimi; Larry W Kwak; Peter McLaughlin; Maria Alma Rodriguez; Jorge Enrique Romaguera; Felipe Samaniego; Anas Younes; Fredrick B Hagemeister
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
Clinical lymphoma, myeloma & leukemia 2013;13(1):15-8.
2012: Anas Younes; Amanda Copeland; Silvana de Castro Faria; Kantharaj Ethirajulu; Michelle A Fanale; Fredrick Hagemeister; Stefan Hart; Ramesh Jayaraman; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Jorge Romaguera; Jatin Shah; Jeanette Wood; Joy Zhu
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(33):4161-7.
2012: Anas Younes; Donald A Berry
From drug discovery to biomarker-driven clinical trials in lymphoma.
Nature reviews. Clinical oncology 2012;9(11):643-53.
2012: Amanda Copeland; Anas Younes
Current treatment strategies in Hodgkin lymphomas.
Current opinion in oncology 2012;24(5):466-74.
2012: Anas Younes; Amanda Copeland; Michelle A Fanale; Silvana de Castro Farial; Luis Fayad; Fredrick Hagemeister; Stella Kim; Larry W Kwak; John M Lambert; Rodica Morariu-Zamfir; Sattva S Neelapu; Sandrine Payrard; Jorge Romaguera; Leo I Gordon
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(22):2776-82.
2012: Daniela Buglio; Kate Byth; Sattva S Neelapu; Sangeetha Palakurthi; Jamal Saeh; Dorin Toader; Francisco Vega; Anas Younes
Essential role of TAK1 in regulating mantle cell lymphoma survival.
Blood 2012;120(2):347-55.
2012: Michael Wang; Anas Younes; Ken H Young; Jerome Zeldis; Liang Zhang; Felipe Samaniego; Luhong Sun; Nicolaus Wagner-Bartak; Maria Badillo; Maria Bejarano; Neda Bell; Catriona Byrne; Fernando Cabanillas; Richard Champlin; Wendy Chen; Yiming Chen; Michelle A Fanale; Luis Fayad; Lei Feng; Nathan Fowler; Fredrick Hagemeister; Kimberly Hartig; Larry W Kwak; Peter McLaughlin; Sattva S Neelapu; Kate J Newberry; Jorge Romaguera
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
The lancet oncology 2012;13(7):716-23.
2012: Anas Younes; Pier Luigi Zinzani; Dina Ben-Yehuda; Jennifer Gallagher; Simon J Harrison; Patrick Johnston; Mark Kirschbaum; Christophe Le Corre; Tee-Chuan Ong; H Miles Prince; Angela Shen; Anna Sureda; Andreas Engert
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2197-203.
2012: Anas Younes; Stephen M Ansell; Nancy L Bartlett; Bruce D Cheson; Joseph Michael Connors; Sven de Vos; Andreas Engert; Andres Forero-Torres; Ajay K Gopal; Dana A Kennedy; Emily K Larsen; Craig H Moskowitz; Rod Ramchandren; Joseph D Rosenblatt; Kerry J Savage; Eric L Sievers; Scott E Smith; Robert Chen
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(18):2183-9.
2012: S Vadhan-Raj; M Wang; Anas Younes; X Zhou; Felipe Samaniego; N J Sarlis; J Shah; C E Bueso-Ramos; J E Cortes; Michelle A Fanale; Luis Fayad; N Fowler; Fredrick B Hagemeister; Larry W Kwak; P W McLaughlin; Robert Z Orlowski; Barbara Pro; A Rodriguez; Jorge Romaguera
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(6):1640-5.
2012: Yasuhiro Oki; Anas Younes
Brentuximab vedotin in systemic T-cell lymphoma.
Expert opinion on biological therapy 2012;12(5):623-32.
2012: Nicolas Batty; Amanda Copeland; Bouthaina S Dabaja; Lei Feng; Fredrick B Hagemeister; Peter McLaughlin; Maria A Rodriguez; Jorge E Romaguera; Felipe Samaniego; Anas Younes
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study.
Leukemia & lymphoma 2012;53(5):801-6.
2012: Yasuhiro Oki; Jorge Romaguera; Amanda Copeland; Michelle Fanale; Silvana de Castro Faria; Luis Fayad; Percy Ivy; L Jeffrey Medeiros; Anas Younes
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.
Leukemia & lymphoma 2012;53(5):990-2.
2012: Anas Younes
Early-stage hodgkin's lymphoma: in pursuit of perfection.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(9):895-6.
2012: Yasuhiro Oki; Jorge Romaguera; Amanda Copeland; Michelle Fanale; Luis E Fayad; Fredrick Hagemeister; Anas Younes
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
Blood 2012;119(9):2171-2.
2012: Paolo Anderlini; Sandra Acholonu; Amin Alousi; Christina Chancoco; Stefan Ciurea; Michelle A Fanale; Chitra M Hosing; Issa F Khouri; Celina Ledesma; Yago Nieto; Uday R Popat; Rima M Saliba; Elizabeth J Shpall; Rosamar Valverde; Anas Younes; Richard E Champlin
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Leukemia & lymphoma 2012;53(3):499-502.
2012: Kensuke Kojima; Vivian Ruvolo; Felipe Samaniego; Anas Younes; Seshagiri Duvvuri; Michael Andreeff
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.
Cancer 2012;118(4):1023-31.
2012: Wesley Greaves; Kranthi Kunkalla; Cynthia S Liang; L Jeffrey Medeiros; Beatriz Sanchez-Espiridion; Rajesh R Singh; Lianchun Xiao; Anas Younes; Kunal S Dave; Francisco Vega
Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols.
Journal of hematology & oncology 2012;5():47.
2012: Andres Forero-Torres; Dana A Kennedy; Joseph D Rosenblatt; Ranjana Advani; Nancy L Bartlett; Michelle A Fanale; Anas Younes
Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.
The oncologist 2012;17(8):1073-80.
2011: Anas Younes; L Jeffrey Medeiros; Sattva S Neelapu; Yasuhiro Oki; Tracy Patterson; Jessica K Paulus; M Renee Ward; Jeffrey M Besterman; R Gregory Bociek; Daniela Buglio; Amanda Copeland; Michel Drouin; Michelle Fanale; Ahmed Galal; Yuan Ji; John Kuruvilla; Zuomei Li; Robert E Martell
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
The lancet oncology 2011;12(13):1222-8.
2011: Anas Younes
CD30-targeted antibody therapy.
Current opinion in oncology 2011;23(6):587-93.
2011: Jessica Katz; John E Janik; Anas Younes
Brentuximab Vedotin (SGN-35).
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(20):6428-36.
2011: Adám Jóna; Noor Khaskhely; L Jeffrey Medeiros; Jessica A Shafer; Catherine M Bollard; Daniela Buglio; Enrico Derenzini; Arpád Illés; Yuan Ji; Anas Younes
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Experimental hematology 2011;39(10):1007-1017.e1.
2011: Anas Younes; Anton Hagenbeek; Bertrand Coiffier
Optimising the lymphoma response criteria in the era of targeted therapy.
The lancet oncology 2011;12(7):616-7.
2011: Michelle Fanale; Luis Fayad; Sandra Horowitz; Yuan Ji; Larry W Kwak; Mary Joy Liboon; Cesar Nunez; Uday Popat; Barbara Pro; Felipe Samaniego; Paolo Anderlini; Anas Younes
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
British journal of haematology 2011;154(2):284-6.
2011: Yasuhiro Oki; Amanda Copeland; Anas Younes
Clinical development of panobinostat in classical Hodgkin's lymphoma.
Expert review of hematology 2011;4(3):245-52.
2011: Yanis Boumber; Anas Younes; Guillermo Garcia-Manero
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor.
Expert opinion on investigational drugs 2011;20(6):823-9.
2011: Daniela Buglio; Noor M Khaskhely; Kui Shin Voo; Hector Martinez-Valdez; Yong-Jun Liu; Anas Younes
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.
Blood 2011;117(10):2910-7.
2011: B C Potts; M X Albitar; Kenneth C Anderson; S Baritaki; C Berkers; B Bonavida; J Chandra; D Chauhan; J C Cusack; W Fenical; I M Ghobrial; M Groll; P R Jensen; K S Lam; G K Lloyd; W McBride; D J McConkey; C P Miller; S T C Neuteboom; Y Oki; H Ovaa; F Pajonk; P G Richardson; A M Roccaro; C M Sloss; M A Spear; E Valashi; Anas Younes; Michael A Palladino
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Current cancer drug targets 2011;11(3):254-84.
2011: Anas Younes
Beyond chemotherapy: new agents for targeted treatment of lymphoma.
Nature reviews. Clinical oncology 2011;8(2):85-96.
2011: Anas Younes; Nousheen Samad
Utility of mTOR inhibition in hematologic malignancies.
The oncologist 2011;16(6):730-41.
2011: Enrico Derenzini; Anas Younes
Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances.
Genome medicine 2011;3(4):26.
2011: Claudia M Monroy; Andrea C Cortes; Mirtha S Lopez; Anthony M D'Amelio; Carol J Etzel; Anas Younes; Sara S Strom; Randa A el-Zein
Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes.
Molecular carcinogenesis 2011;50(1):36-46.
2010: Anas Younes; Julie M Vose; Andrew D Zelenetz; M R Smith; H A Burris; S M Ansell; J Klein; W Halpern; R Miceli; E Kumm; N L Fox; Myron S Czuczman
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.
British journal of cancer 2010;103(12):1783-7.
2010: Manuela Lemoine; Anas Younes
Histone deacetylase inhibitors in the treatment of lymphoma.
Discovery medicine 2010;10(54):462-70.
2010: Amanda Copeland; Daniela Buglio; Anas Younes
Histone deacetylase inhibitors in lymphoma.
Current opinion in oncology 2010;22(5):431-6.
2010: Jorge Romaguera; Luis Fayad; Lei Feng; Kimberly Hartig; Pamela Weaver; Maria Alma Rodriguez; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Fernando Cabanillas; Andrew Lamb; Larry Kwak; Michael Wang
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
British journal of haematology 2010;150(2):200-8.
2010: Yasuhiro Oki; Anas Younes
Does rituximab have a place in treating classic hodgkin lymphoma?
Current hematologic malignancy reports 2010;5(3):135-9.
2009: Michael Wang; Yasuhiro Oki; Barbara Pro; Jorge Romaguera; Maria Alma Rodriguez; Felipe Samaniego; Peter McLaughlin; Fredrick Hagemeister; Sattva S Neelapu; Amanda Copeland; Barry Samuels; Evelyne M Loyer; Yuan Ji; Anas Younes
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(31):5213-8.
2009: Anas Younes; F Wong
Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(6):1147-8.
2009: Anas Younes
New investigational drugs for lymphoma.
Clinical advances in hematology & oncology : H&O 2009;7(5):308-10.
2009: Anas Younes
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2009;():507-19.
2008: Barbara Pro; Brian Leber; Mitchell Smith; Luis Fayad; Jorge Romaguera; Fredrick Hagemeister; Alma Rodriguez; Peter McLaughlin; Felipe Samaniego; James Zwiebel; Adriana Lopez; Larry Kwak; Anas Younes
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma.
British journal of haematology 2008;143(3):355-60.
2008: Daniela Buglio; Georgios V Georgakis; Shino Hanabuchi; Kazuhiko Arima; Noor M Khaskhely; Yong-Jun Liu; Anas Younes
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.
Blood 2008;112(4):1424-33.
2008: Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.
Blood 2008;112(3):711-20.
2008: Grace Suh; Anas Younes
Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma.
Nature clinical practice. Oncology 2008;5(7):368-9.
2008: Anas Younes
Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers.
Autophagy 2008;4(5):707-9.
2008: John P Leonard; Stephanie A Gregory; David G Maloney; Julie M Vose; Anas Younes; Andrew D Zelenetz
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Clinical advances in hematology & oncology : H&O 2008;6(6):437-45.
2008: Bertrand Coiffier; Arnold Altman; Ching-Hon Pui; Anas Younes; Mitchell S Cairo
Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(16):2767-78.
2008: Yasuhiro Oki; Anas Younes
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
Leukemia & lymphoma 2008;49(5):883-9.
2008: Victor Y Yazbeck; Daniela Buglio; Georgios V Georgakis; Yang Li; Eiji Iwado; Jorge E Romaguera; Seiji Kondo; Anas Younes
Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Experimental hematology 2008;36(4):443-50.
2008: M J Overman; L Feng; Barbara Pro; Peter McLaughlin; Mark Hess; Felipe Samaniego; Anas Younes; Jorge Romaguera; Fredrick B Hagemeister; Larry W Kwak; Fernando Cabanillas; Maria A Rodriguez; Luis Fayad
The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):553-9.
2008: Yasuhiro Oki; Barbara Pro; Luis Fayad; Jorge Romaguera; Felipe Samaniego; Fredrick Hagemeister; Sattva S Neelapu; Peter McLaughlin; Andre Goy; Anas Younes
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Cancer 2008;112(4):831-6.
2008: Nancy L Bartlett; Anas Younes; Matthew H Carabasi; Andres Forero; Joseph D Rosenblatt; John P Leonard; Steven H Bernstein; R Gregory Bociek; Jennie M Lorenz; Bruce W Hart; Jeremy Barton
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.
Blood 2008;111(4):1848-54.
2008: Paolo Anderlini; Rima M Saliba; Sandra Acholonu; Sergio Giralt; Borje Andersson; Naoto T Ueno; Chitra Hosing; Issa F Khouri; Daniel Couriel; Marcos De Lima; Muzaffar H Qazilbash; Barbara Pro; Jorge Romaguera; Luis Fayad; Fredrick Hagemeister; Anas Younes; Mark F Munsell; Richard E Champlin
Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Haematologica 2008;93(2):257-64.
2008: Michelle A Fanale; Anas Younes
Nodular lymphocyte predominant Hodgkin's lymphoma.
Cancer treatment and research 2008;142():367-81.
2007: Amanda Wedgwood; Anas Younes
Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.
Clinical lymphoma & myeloma 2007;8 Suppl 2():S63-6.
2007: Kwang Seok Ahn; Gautam Sethi; Ta-Hsiang Chao; Saskia T C Neuteboom; Madan M Chaturvedi; Michael A Palladino; Anas Younes; Bharat B Aggarwal
Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products.
Blood 2007;110(7):2286-95.
2007: Yasuhiro Oki; Georgios V Georgakis; Thi-Sau Migone; Larry W Kwak; Anas Younes
Elevated serum BLyS levels in patients with non-Hodgkin lymphoma.
Leukemia & lymphoma 2007;48(9):1869-71.
2007: Elias Jabbour; Chitra Hosing; Gregory D Ayers; Rodolfo Nunez; Paolo Anderlini; Barbara Pro; Issa Khouri; Anas Younes; Fredrick Hagemeister; Larry W Kwak; Luis Fayad
Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
Cancer 2007;109(12):2481-9.
2007: Daniela Buglio; Georgios V Georgakis; Anas Younes
Novel small-molecule therapy of Hodgkin lymphoma.
Expert review of anticancer therapy 2007;7(5):735-40.
2007: Yasuhiro Oki; Anas Younes
Endothelial progenitor cells in non-Hodgkin's lymphoma.
Haematologica 2007;92(4):433-4.
2007: Suizhao Wang; Shu Wang; Hoyoung Maeng; Daniel P Young; Om Prakash; Luis Fayad; Anas Younes; Felipe Samaniego
K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis.
Blood 2007;109(5):2174-82.
2007: Yasuhiro Oki; Georgios V Georgakis; Thi-Sau Migone; Larry W Kwak; Anas Younes
Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.
Haematologica 2007;92(2):269-70.
2007: Michelle A Fanale; Anas Younes
Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Drugs 2007;67(3):333-50.
2007: Yasuhiro Oki; Peter McLaughlin; Luis Fayad; Barbara Pro; Paul F Mansfield; Gary L Clayman; L Jeffrey Medeiros; Larry W Kwak; Pramod K Srivastava; Anas Younes
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
Cancer 2007;109(1):77-83.
2006: Georgios V Georgakis; Yang Li; George Z Rassidakis; L Jeffrey Medeiros; Anas Younes
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Experimental hematology 2006;34(12):1670-9.
2006: Anas Younes; Luis Fayad; Jorge Romaguera; Barbara Pro; Andre Goy; Michael Wang
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2976-81.
2006: Amanda Wedgwood; Anas Younes
Targeting lymphoma cells and their microenvironment with novel antibodies.
Clinical lymphoma & myeloma 2006;7 Suppl 1():S33-40.
2006: Georgios V Georgakis; Yang Li; Anas Younes
The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
British journal of haematology 2006;135(1):68-71.
2006: Barbara Pro; Fredrick B Hagemeister; Peter McLaughlin; Jorge Romaguera; Maria A Rodriguez; Fernando Cabanillas; Lili Paz Tiongson; Anas Younes
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 2006;47(9):1818-21.
2006: Victor Yazbeck; Georgios V Georgakis; Amanda Wedgwood; Anas Younes
Hodgkin's lymphoma: molecular targets and novel treatment strategies.
Future oncology (London, England) 2006;2(4):533-51.
2006: Qi Liu; Luis Fayad; Fernando Cabanillas; Fredrick B Hagemeister; Gregory D Ayers; Mark Hess; Jorge Romaguera; Maria A Rodriguez; Apostolia-Maria Tsimberidou; Srdan Verstovsek; Anas Younes; Barbara Pro; Ming-Sheng Lee; Ana Ayala; Peter McLaughlin
Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1582-9.
2006: Luis Fayad; Anas Younes
Novel treatment strategies for aggressive non-Hodgkin's lymphoma.
Expert opinion on pharmacotherapy 2006;7(6):733-48.
2006: Harrys A Torres; Dimitrios P Kontoyiannis; Elizabeth A Aguilera; Anas Younes; Mario A Luna; Jeffrey J Tarrand; Graciela M Nogueras; Issam I Raad; Roy F Chemaly
Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality.
Clinical lymphoma & myeloma 2006;6(5):393-8.
2006: Mamoun Younes; Georgios V Georgakis; Mahdis Rahmani; David G Beer; Anas Younes
Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
European journal of cancer (Oxford, England : 1990) 2006;42(4):542-7.
2006: Barbara Pro; Luis Fayad; Peter McLaughlin; Jorge Romaguera; Fredrick B Hagemeister; Maria A Rodriguez; Andre Goy; Evelyne M Loyer; Anas Younes
Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma.
Leukemia & lymphoma 2006;47(3):481-5.
2006: Anas Younes; Barbara Pro; Luis Fayad
Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.
Blood 2006;107(4):1731-2.
2006: Georgios V Georgakis; Yang Li; George Z Rassidakis; L Jeffrey Medeiros; Gordon B Mills; Anas Younes
Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
British journal of haematology 2006;132(4):503-11.
2006: Georgios V Georgakis; Yang Li; George Z Rassidakis; Hector Martinez-Valdez; L Jeffrey Medeiros; Anas Younes
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(2):584-90.
2006: Georgios V Georgakis; Anas Younes
From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
Expert review of anticancer therapy 2006;6(1):131-40.
2005: Anas Younes
Angiogenesis in lymphoma: a short review.
Current molecular medicine 2005;5(7):609-13.
2005: Jorge Romaguera; Luis Fayad; Maria A Rodriguez; Kristine Broglio; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth Katz; Harish K Gagneja; Barry Samuels; Terry L Smith; Fernando Cabanillas
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7013-23.
2005: Jose R Valbuena; George Z Rassidakis; Pei Lin; Coralyn Atwell; Georgios V Georgakis; Anas Younes; Dan Jones; L Jeffrey Medeiros
Expression of heat-shock protein-90 in non-Hodgkin's lymphomas.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005;18(10):1343-9.
2005: Roy F Chemaly; Harrys A Torres; Ray Hachem; Graciela M Nogueras; Elizabeth A Aguilera; Anas Younes; Mario A Luna; Gilhen Rodriguez; Jeffrey J Tarrand; Issam I Raad
Cytomegalovirus pneumonia in patients with lymphoma.
Cancer 2005;104(6):1213-20.
2005: Chul Ha; Fernando Cabanillas; Ming S Lee; Susan L Tucker; Peter McLaughlin; Maria A Rodriguez; Anas Younes; Jorge Romaguera; Ofelia M Mesina; James D Cox
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
International journal of radiation oncology, biology, physics 2005;63(1):188-93.
2005: Yasuhiro Oki; Peter McLaughlin; Barbara Pro; Fredrick B Hagemeister; Archie Bleyer; Evelyne M Loyer; Anas Younes
Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.
Cancer 2005;104(4):781-7.
2005: Georgios V Georgakis; Yang Li; Robin Humphreys; Michael Andreeff; Susan O'Brien; Mamoun Younes; Antonino Carbone; Vivian Albert; Anas Younes
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death.
British journal of haematology 2005;130(4):501-10.
2005: Apostolia-Maria Tsimberidou; Anas Younes; Jorge Romaguera; Fredrick B Hagemeister; Maria A Rodriguez; Lei Feng; Ana Ayala; Terry L Smith; Fernando Cabanillas; Peter McLaughlin
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Cancer 2005;104(2):345-53.
2005: Amanda Wedgwood; Barbara Pro; Anas Younes
The lymphomas: molecular pathways and novel therapeutic targets.
Current hematology reports 2005;4(4):324-34.
2005: Myron S Czuczman; Aron Thall; Thomas E Witzig; Julie M Vose; Anas Younes; Christos Emmanouilides; Thomas P Miller; Joseph O Moore; John P Leonard; Leo I Gordon; John Sweetenham; Baha Alkuzweny; Deborah M Finucane; Bryan R Leigh
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(19):4390-8.
2005: Paolo Anderlini; Rima M Saliba; Sandra Acholonu; Grace-Julia Okoroji; Michele Donato; Sergio Giralt; Borje Andersson; Naoto T Ueno; Issa Khouri; Marcos De Lima; Chitra Hosing; Agueda Cohen; Cindy Ippoliti; Jorge Romaguera; M A Rodriguez; Barbara Pro; Luis Fayad; Andre Goy; Anas Younes; Richard E Champlin
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
Bone marrow transplantation 2005;35(10):943-51.
2005: Georgios V Georgakis; Anas Younes
Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
Future oncology (London, England) 2005;1(2):273-81.
2005: Issa F Khouri; Rima M Saliba; Chitra Hosing; Grace-Julia Okoroji; Sandra Acholonu; Paolo Anderlini; Daniel Couriel; Marcos De Lima; Michele L Donato; Luis Fayad; Sergio Giralt; Roy Jones; Martin Korbling; Farzaneh Maadani; John T Manning; Barbara Pro; Elizabeth J Shpall; Anas Younes; Peter McLaughlin; Richard E Champlin
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2240-7.
2005: Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge Romaguera; Fredrick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang; Kristine Broglio; Barry Samuels; Frederic Gilles; Andreas H Sarris; Susan Hart; Elizabeth Trehu; David P Schenkein; Fernando Cabanillas; Alma M Rodriguez
Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):667-75.
2005: Sandra J Horning; Anas Younes; Vinay Jain; Stewart Kroll; Jennifer Lucas; Donald A Podoloff; Michael L Goris
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):712-9.
2005: Georgios V Georgakis; Anas Younes
Cytokines and lymphomas.
Cancer treatment and research 2005;126():69-102.
2004: Anas Younes
New treatment strategies for aggressive lymphoma.
Seminars in oncology 2004;31(6 Suppl 15):10-3.
2004: Nam H Dang; Fredrick B Hagemeister; Barbara Pro; Peter McLaughlin; Jorge Romaguera; Dan Jones; Barry Samuels; Felipe Samaniego; Anas Younes; Michael Wang; Andre Goy; Maria A Rodriguez; Pamela L Walker; Yolanda Arredondo; Ann T Tong; Luis Fayad
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(20):4095-102.
2004: Marina Konopleva; Elena Elstner; Teresa McQueen; Twee Tsao; Andrey Sudarikov; Wei Hu; Wendy D Schober; Rui-Yu Wang; David Chism; Steven M Kornblau; Anas Younes; Steven J Collins; H Phillip Koeffler; Michael Andreeff
Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.
Molecular cancer therapeutics 2004;3(10):1249-62.
2004: Barbara Pro; Anas Younes
New molecular targets for treatment of lymphoma.
Current oncology reports 2004;6(5):360-8.
2004: Anas Younes; Barbara Pro; Michael J Robertson; Ian W Flinn; Jorge Romaguera; Fredrick Hagemeister; Nam H Dang; Paolo Fiumara; Evelyne M Loyer; Fernando Cabanillas; Peter W McLaughlin; Maria A Rodriguez; Felipe Samaniego
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5432-8.
2004: Yasuhiro Oki; Anas Younes
Heat shock protein-based cancer vaccines.
Expert review of vaccines 2004;3(4):403-11.
2004: George Z Rassidakis; Georgios V Georgakis; Mauricio P Oyarzo; Anas Younes; L Jeffrey Medeiros
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2004;17(8):946-53.
2004: Bei Zheng; Georgios V Georgakis; Yang Li; Alok C Bharti; David J McConkey; Bharat B Aggarwal; Anas Younes
Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):3207-15.
2004: Barbara Pro; Anas Younes; Maher Albitar; Nam H Dang; Felipe Samaniego; Jorge Romaguera; Peter McLaughlin; Fredrick B Hagemeister; Maria A Rodriguez; Marilyn Clemons; Fernando Cabanillas
Thalidomide for patients with recurrent lymphoma.
Cancer 2004;100(6):1186-9.
2003: George Z Rassidakis; Georgios V Georgakis; Anas Younes; L Jeffrey Medeiros
c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma.
Blood 2003;102(13):4619-20.
2003: Anas Younes
A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphoma.
Clinical lymphoma 2003;4(3):183-5.
2003: Issa F Khouri; Ming-S Lee; Rima M Saliba; Gu Jun; Luis Fayad; Anas Younes; Barbara Pro; Sandra Acholonu; Peter McLaughlin; Ruth Katz; Richard E Champlin
Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4407-12.
2003: Anas Younes; Marshall E Kadin
Emerging applications of the tumor necrosis factor family of ligands and receptors in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(18):3526-34.
2003: Anas Younes; Antonio Carbone
Clinicopathologic and molecular features of Hodgkin's lymphoma.
Cancer biology & therapy 2003;2(5):500-7.
2003: Xiaoping Sun; Kung-Chao Chang; Lynne V Abruzzo; Raymond Lai; Anas Younes; Dan Jones
Epidermal growth factor receptor expression in follicular dendritic cells: a shared feature of follicular dendritic cell sarcoma and Castleman's disease.
Human pathology 2003;34(9):835-40.
2003: Rebecca F Yorke; Anas Younes; Minni Chirala; Mamoun Younes
Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia.
European journal of cancer (Oxford, England : 1990) 2003;39(14):2099-102.
2003: Nam H Dang; Fredrick B Hagemeister; Madeleine Duvic; Jorge Romaguera; Anas Younes; Dan Jones; Barry Samuels; Luis Fayad; Barbara Pro; Felipe Samaniego; Andreas H Sarris; Andre Goy; Peter McLaughlin; Ann T Tong; Pamela L Walker; Lili Paz Tiongson; Terry L Smith; Yang O Huh; Chikao Morimoto; Maria A Rodriguez
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.
Oncology reports 2003;10(5):1513-8.
2003: Anas Younes; Bharat B Aggarwall
Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders.
Cancer 2003;98(3):458-67.
2003: Bei Zheng; Paolo Fiumara; Yang V Li; Georgios V Georgakis; Virginia Snell; Mamoun Younes; Jean-Nicolas Vauthey; Antonino Carbone; Anas Younes
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.
Blood 2003;102(3):1019-27.
2003: Anas Younes; Jorge Romaguera; Fredrick Hagemeister; Peter McLaughlin; Maria A Rodriguez; Paolo Fiumara; Andre Goy; Sima Jeha; John T Manning; Dan Jones; Lynne V Abruzzo; L Jeffrey Medeiros
A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.
Cancer 2003;98(2):310-4.
2003: Anas Younes; Amit Garg; Bharat B Aggarwal
Nuclear transcription factor-kappaB in Hodgkin's disease.
Leukemia & lymphoma 2003;44(6):929-35.
2003: Anas Younes; Kandasamy Hariharan; Roberta S Allen; Bryan R Leigh
Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma.
Clinical lymphoma 2003;3(4):257-9.
2003: Jorge Romaguera; L Jeffrey Medeiros; Fredrick B Hagemeister; Luis Fayad; Maria A Rodriguez; Barbara Pro; Anas Younes; Peter McLaughlin; Andre Goy; Andreas H Sarris; Nam H Dang; Felipe Samaniego; H M Brown; Harish K Gagneja; Fernando Cabanillas
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma.
Cancer 2003;97(3):586-91.
2003: Gregory M Chronowski; Richard B Wilder; Susan L Tucker; Chul Ha; Anas Younes; Luis Fayad; Maria A Rodriguez; Fredrick B Hagemeister; Ibrahim Barista; Fernando Cabanillas; James D Cox
Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
International journal of radiation oncology, biology, physics 2003;55(1):36-43.
2002: Apostolia-Maria Tsimberidou; Peter McLaughlin; Anas Younes; Maria A Rodriguez; Fredrick B Hagemeister; Andreas H Sarris; Jorge Romaguera; Mark Hess; Terry L Smith; Ying Yang; Ana Ayala; Alejandro Preti; Ming-Sheng Lee; Fernando Cabanillas
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Blood 2002;100(13):4351-7.
2002: Michael L Wang; Anas Younes
Testicular lymphoma: a mysterious link between the testis and the brain.
Clinical lymphoma 2002;3(3):173-4.
2002: Pamela J Schlembach; Richard B Wilder; Dan Jones; Chul Ha; Luis Fayad; Anas Younes; Fredrick Hagemeister; Mark Hess; Fernando Cabanillas; James D Cox
Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
Cancer journal (Sudbury, Mass.) 2002;8(5):377-83.
2002: Richard B Wilder; Pamela J Schlembach; Dan Jones; Gregory M Chronowski; Chul Ha; Anas Younes; Fredrick B Hagemeister; Ibrahim Barista; Fernando Cabanillas; James D Cox
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
Cancer 2002;94(6):1731-8.
2002: Katharina Clodi; Zahra Asgari; Mamoun Younes; J Lynn Palmer; Fernando Cabanillas; Antonino Carbone; Michael Andreeff; Anas Younes
Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.
Cancer 2002;94(1):1-5.
2001: Issa F Khouri; Rima M Saliba; Sergio Giralt; Ming-Sheng Lee; Grace-Julia Okoroji; Fredrick B Hagemeister; Martin Korbling; Anas Younes; Cindy Ippoliti; James L Gajewski; Peter McLaughlin; Paolo Anderlini; Michele L Donato; Fernando Cabanillas; Richard E Champlin
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Blood 2001;98(13):3595-9.
2001: Paolo Fiumara; Virginia Snell; Yang Li; A Mukhopadhyay; Mamoun Younes; Ann M Gillenwater; Fernando Cabanillas; Bharat B Aggarwal; Anas Younes
Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines.
Blood 2001;98(9):2784-90.
2001: Deborah Witte; Minni Chirala; Anas Younes; Y Li; Mamoun Younes
Estrogen receptor beta is expressed in human colorectal adenocarcinoma.
Human pathology 2001;32(9):940-4.
2001: J Rodriguez; Mark F Munsell; Salim Yazji; Fredrick B Hagemeister; Anas Younes; Borje Andersson; Sergio Giralt; James L Gajewski; Marcos De Lima; Daniel Couriel; Jorge Romaguera; Fernando Cabanillas; Richard E Champlin; Issa F Khouri
Impact of high-dose chemotherapy on peripheral T-cell lymphomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3766-70.
2001: K M King; Anas Younes
Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
Expert review of anticancer therapy 2001;1(2):177-86.
2001: Anas Younes; H Alejandro Preti; Fredrick B Hagemeister; Peter McLaughlin; Jorge Romaguera; Maria A Rodriguez; Barry Samuels; J Lynn Palmer; Fernando Cabanillas
Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(7):923-7.
2001: Andreas H Sarris; Jorge Romaguera; Fredrick B Hagemeister; Maria A Rodriguez; Peter McLaughlin; Barbara Pro; Anas Younes; Ofelia M Mesina; Fernando Cabanillas; L Jeffrey Medeiros; Barry Samuels
Irinotecan in relapsed or refractory non-Hodgkin's lymphoma.
Oncology (Williston Park, N.Y.) 2001;15(7 Suppl 8):53-6.
2001: Anupama Munshi; G Pappas; T Honda; Timothy J McDonnell; Anas Younes; Yang Li; Raymond E Meyn
TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
Oncogene 2001;20(29):3757-65.
2001: Satoshi Takahashi; Patricia Yotnda; Raphael Rousseau; Zhuyong Mei; S Smith; Donna R Rill; Anas Younes; Malcolm K Brenner
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Cancer gene therapy 2001;8(5):378-87.
2001: Paolo Fiumara; Anas Younes
CD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.
British journal of haematology 2001;113(2):265-74.
2001: S Mann; Rodolfo Laucirica; N Carlson; Pamela S Younes; N Ali; Anas Younes; Y Li; Mamoun Younes
Estrogen receptor beta expression in invasive breast cancer.
Human pathology 2001;32(1):113-8.
2000: Anas Younes; M Cristofanilli; Peter McLaughlin; Fredrick B Hagemeister; Donna Weber; Ofelia M Mesina; Fernando Cabanillas
Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma.
Leukemia & lymphoma 2000;40(1-2):79-85.
2000: Peter McLaughlin; Fredrick B Hagemeister; Maria A Rodriguez; Andreas H Sarris; O Pate; Anas Younes; Ming-Sheng Lee; Nam H Dang; Jorge Romaguera; Alejandro Preti; N McAda; Fernando Cabanillas
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Seminars in oncology 2000;27(6 Suppl 12):37-41.
2000: Katharina Clodi; D Wimmer; Yang Li; R Goodwin; U Jaeger; G Mann; Helmut Gadner; Anas Younes
Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells.
British journal of haematology 2000;111(2):580-6.
2000: Andreas H Sarris; A Psyrri; Fredrick Hagemeister; Jorge Romaguera; Peter McLaughlin; Maria A Rodriguez; CR Bachier; Anas Younes; Ofelia M Mesina; M Oholendt; L Jeffrey Medeiros; Barry Samuels; Laurel M Adams; Fernando Cabanillas
Infusional vinorelbine in relapsed or refractory lymphomas.
Leukemia & lymphoma 2000;39(3-4):291-9.
2000: Jorge Romaguera; Issa F Khouri; Hagop M Kantarjian; Fredrick B Hagemeister; Maria A Rodriguez; Peter McLaughlin; Andreas H Sarris; Anas Younes; Jose Rodriguez; Fernando Cabanillas
Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients.
Leukemia & lymphoma 2000;39(1-2):77-85.
2000: Mamoun Younes; Juan Lechago; Atilla Ertan; D Finnie; Anas Younes
Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus.
Human pathology 2000;31(4):434-8.
2000: K King; Anas Younes
Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
Seminars in oncology 2000;27(1 Suppl 1):14-22.
2000: Mamoun Younes; Mary R Schwartz; Atilla Ertan; D Finnie; Anas Younes
Fas ligand expression in esophageal carcinomas and their lymph node metastases.
Cancer 2000;88(3):524-8.
2000: A López-Guillermo; Fernando Cabanillas; Peter McLaughlin; T Smith; Fredrick Hagemeister; MA Rodríguez; Jorge Romaguera; Anas Younes; Andreas H Sarris; H Alejandro Preti; WC Pugh; Ming-Sheng Lee
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 1():137-40.
1999: Mamoun Younes; Mary R Schwartz; D Finnie; Anas Younes
Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus.
Human pathology 1999;30(11):1309-13.
1999: Michele L Donato; Richard E Champlin; Koen van Besien; Martin Korbling; Fernando Cabanillas; Paolo Anderlini; J G Gajewski; Jo Lauppe; April Durett; Borje Andersson; Sergio Giralt; Issa Khouri; Fredrick Hagemeister; Jorge Romaguera; Andreas H Sarris; Peter McLaughlin; Anas Younes; Cindy Ippoliti; D A Blamble; Jeane Hester; Adrian Gee; Maria A Rodriguez
Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Leukemia & lymphoma 1999;35(3-4):317-24.
1999: Shourong Zhao; Z Asgary; Yibin Wang; R Goodwin; Michael Andreeff; Anas Younes
Functional expression of TRAIL by lymphoid and myeloid tumour cells.
British journal of haematology 1999;106(3):827-32.
1999: JP Ayoub; J L Palmer; Yang Huh; Fernando Cabanillas; Anas Younes
Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease.
Leukemia & lymphoma 1999;34(5-6):519-27.
1999: A López-Guillermo; Fernando Cabanillas; Timothy J McDonnell; Peter McLaughlin; T Smith; WC Pugh; Fredrick Hagemeister; MA Rodríguez; Jorge Romaguera; Anas Younes; Andreas H Sarris; H Alejandro Preti; Ming-Sheng Lee
Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
Blood 1999;93(9):3081-7.
1999: Anas Younes
Paclitaxel-based treatment of lymphoma.
Seminars in oncology 1999;26(1 Suppl 2):123-8.
1999: Jorge Romaguera; Maria A Rodriguez; Fredrick B Hagemeister; Peter McLaughlin; J Rodriguez; A Preti; Anas Younes; Andreas H Sarris; Fernando Cabanillas
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination.
Investigational new drugs 1999;17(2):187-92.
1999: Marina Konopleva; S Zhao; Z Xie; Harry Segall; Anas Younes; David F Claxton; Zeev Estrov; S M Kornblau; Michael Andreeff
Apoptosis. Molecules and mechanisms.
Advances in experimental medicine and biology 1999;457():217-36.
1998: Jorge Romaguera; Fredrick B Hagemeister; Peter McLaughlin; Maria A Rodriguez; CR Bachier; H Alejandro Preti; Andreas H Sarris; Donna Weber; Anas Younes; Fernando Cabanillas
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Leukemia & lymphoma 1998;32(1-2):97-106.
1998: Anas Younes; Jorge Romaguera; Ofelia M Mesina; Fredrick Hagemeister; Andreas H Sarris; Maria A Rodriguez; Peter McLaughlin; H Alejandro Preti; CR Bachier; Fernando Cabanillas
Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
British journal of haematology 1998;103(3):678-83.
1998: Issa F Khouri; Jorge Romaguera; Andrew Lamb; J Lynn Palmer; WC Pugh; Martin Korbling; Fredrick Hagemeister; Barry Samuels; A Rodriguez; Sergio Giralt; Anas Younes; Donna Przepiorka; David F Claxton; Fernando Cabanillas; Richard Champlin
Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3803-9.
1998: Katharina Clodi; Z Asgary; Shourong Zhao; Kay-Oliver Kliche; Fernando Cabanillas; Michael Andreeff; Anas Younes
Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells.
British journal of haematology 1998;103(1):270-5.
1998: Katharina Clodi; Virginia Snell; Shourong Zhao; Fernando Cabanillas; Michael Andreeff; Anas Younes
Unbalanced expression of Fas and CD40 in mantle cell lymphoma.
British journal of haematology 1998;103(1):217-9.
1998: A López-Guillermo; Fernando Cabanillas; Peter McLaughlin; T Smith; Fredrick Hagemeister; MA Rodríguez; Jorge Romaguera; Anas Younes; Andreas H Sarris; H Alejandro Preti; WC Pugh; Ming-Sheng Lee
The clinical significance of molecular response in indolent follicular lymphomas.
Blood 1998;91(8):2955-60.
1998: Koen van Besien; Chul Ha; S Murphy; Peter McLaughlin; A Rodriguez; K Amin; A Forman; Jorge Romaguera; Fredrick Hagemeister; Anas Younes; CR Bachier; Andreas H Sarris; K S Sobocinski; James D Cox; Fernando Cabanillas
Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.
Blood 1998;91(4):1178-84.
1998: Jorge Romaguera; J Rodríguez Díaz-Pavon; L Carías; Fredrick B Hagemeister; Peter McLaughlin; M A Rodríguez; Andreas H Sarris; Anas Younes; Alejandro Preti; CR Bachier; E Llerena; Fernando Cabanillas
Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients.
Leukemia & lymphoma 1998;28(3-4):295-306.
1998: Anas Younes; Virginia Snell; U Consoli; Katharina Clodi; Shourong Zhao; J Lynn Palmer; EK Thomas; R J Armitage; Michael Andreeff
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
British journal of haematology 1998;100(1):135-41.
1997: Virginia Snell; Katharina Clodi; Shourong Zhao; R Goodwin; EK Thomas; S W Morris; Marshall E Kadin; Fernando Cabanillas; Michael Andreeff; Anas Younes
Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies.
British journal of haematology 1997;99(3):618-24.
1997: R Munker; Anas Younes; Fernando Cabanillas; Michael Andreeff
Soluble CD95 in the serum of patients with low and intermediate grade malignant lymphomas: absence of prognostic correlations.
Leukemia & lymphoma 1997;27(5-6):517-21.
1997: Anas Younes; U Consoli; Virginia Snell; Katharina Clodi; Kay-Oliver Kliche; J Lynn Palmer; H J Gruss; R Armitage; EK Thomas; Fernando Cabanillas; Michael Andreeff
CD30 ligand in lymphoma patients with CD30+ tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(11):3355-62.
1997: Katharina Clodi; Anas Younes
Reed-Sternberg cells and the TNF family of receptors/ligands.
Leukemia & lymphoma 1997;27(3-4):195-205.
1997: Katharina Clodi; Anas Younes; AM Goodacre; M Roberts; J Palmer; Mamoun Younes; Fernando Cabanillas; Michael Andreeff
Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization.
British journal of haematology 1997;98(4):913-21.
1997: Anas Younes; Maria A Rodriguez; Peter McLaughlin; LB North; Andreas H Sarris; O Pate; Fredrick B Hagemeister; Jorge Romaguera; Alejandro Preti; CR Bachier; Fernando Cabanillas
Phase I study of fludarabine and paclitaxel for the treatment of low-grade non-Hodgkin's lymphoma.
Leukemia & lymphoma 1997;26(1-2):77-82.
1997: R J Shade; Anas Younes
In vitro and in vivo biologic effects of interleukin-3 (IL-3) in follicular low-grade lymphoma.
Leukemia & lymphoma 1997;26(1-2):17-25.
1997: JP Ayoub; LB North; J Greer; Fernando Cabanillas; Anas Younes
Pulmonary changes in patients with lymphoma who receive paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2476.
1997: Anas Younes; JP Ayoub; Andreas H Sarris; Fredrick Hagemeister; LB North; O Pate; Peter McLaughlin; Maria A Rodriguez; Jorge Romaguera; R Kurzrock; Alejandro Preti; CR Bachier; T Smith; Fernando Cabanillas
Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
British journal of haematology 1997;96(2):328-32.
1997: Anas Younes; Shourong Zhao; X Zhang; Virginia Snell; Katharina Clodi; Kay-Oliver Kliche; E Thomas; Fernando Cabanillas; Michael Andreeff
CD30-ligand and CD40-ligand expression in lymph nodes involved with Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 2():97-100.
1997: Anas Younes; JP Ayoub; Andreas H Sarris; LB North; O Pate; Peter McLaughlin; Maria A Rodriguez; Jorge Romaguera; Fredrick Hagemeister; CR Bachier; Alejandro Preti; Fernando Cabanillas
Paclitaxel (Taxol) for the treatment of lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8 Suppl 1():129-31.
1996: Anas Younes; Fernando Cabanillas; P W McLaughlin; F B Hagemeister; Charles Michael Farber; Andreas H Sarris; O Pate; J Myers; Carol S Portlock
Preliminary experience with paclitaxel for the treatment of relapsed and refractory Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(10):1083-5.
1996: Anas Younes; U Consoli; Shourong Zhao; Virginia Snell; E Thomas; H J Gruss; Fernando Cabanillas; Michael Andreeff
CD30 ligand is expressed on resting normal and malignant human B lymphocytes.
British journal of haematology 1996;93(3):569-71.
1996: Peter McLaughlin; F B Hagemeister; Jorge Romaguera; Andreas H Sarris; O Pate; Anas Younes; F Swan; Michael Keating; Fernando Cabanillas
Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(4):1262-8.
1996: Anas Younes; Andreas H Sarris; U Consoli; A Rodriguez; Peter McLaughlin; Y Huh; S Starry; Fernando Cabanillas; Michael Andreeff
A pilot study of high-dose interleukin-3 treatment of relapsed follicular small cleaved-cell lymphoma: hematologic, immunologic, and clinical results.
Blood 1996;87(5):1698-703.
1996: Anas Younes; JP Ayoub; F B Hagemeister; Peter McLaughlin; Andreas H Sarris; Maria A Rodriguez; F Swan; Jorge Romaguera; J Martin; Fernando Cabanillas
No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(2):543-8.
1996: Andreas H Sarris; Anas Younes; Peter McLaughlin; D Moore; F Hagemeister; F Swan; Maria A Rodriguez; Jorge Romaguera; LB North; P Mansfield; D Callendar; O Mesina; Fernando Cabanillas
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):233-9.
1995: David Jendiroba; Anas Younes; R Katz; D Hill; Fernando Cabanillas; Michael Andreeff
Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study.
Leukemia 1995;9(7):1144-6.
1995: Anas Younes; David Jendiroba; R Katz; D Hill; Fernando Cabanillas; Michael Andreeff
Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization.
Cancer genetics and cytogenetics 1995;82(1):23-9.
1995: N Touroutoglou; Meletios A Dimopoulos; Anas Younes; M Hess; WC Pugh; J Cox; Fernando Cabanillas; Andreas H Sarris
Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1361-7.
1995: Anas Younes; Shourong Zhao; David Jendiroba; H D Kleine; Fernando Cabanillas; Michael Andreeff
Decreased expression of the deleted in colorectal carcinoma gene in non-Hodgkin's lymphoma.
Blood 1995;85(10):2813-6.
1995: Andreas H Sarris; Alejandro Majlis; Meletios A Dimopoulos; Anas Younes; F Swann; Maria A Rodriguez; Peter McLaughlin; Fernando Cabanillas
Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma.
Leukemia & lymphoma 1995;17(5-6):473-7.
1995: Anas Younes; Andreas H Sarris; A Melnyk; Jorge Romaguera; Peter McLaughlin; F Swan; Maria A Rodriguez; F Hagemeister; D Moore; LB North
Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(3):583-7.
1995: D F Moore; F Swan; J Yau; Maria A Rodriguez; Peter McLaughlin; Andreas H Sarris; Jorge Romaguera; Anas Younes; F B Hagemeister; Fernando Cabanillas
Cyclosporin plus doxorubicin, vincristine and etoposide in the treatment of refractory non-Hodgkin's lymphoma: a phase II study.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1995;7(5):300-3.
1994: Anas Younes; David Jendiroba; H Engel; S Escudier; R Katz; M A Rodriguez; D Hill; Fernando Cabanillas; Michael Andreeff
High incidence of monosomy 18 in lymphoid malignancies that have bone marrow and peripheral blood involvement.
Cancer genetics and cytogenetics 1994;77(1):39-44.
1994: Anas Younes; WC Pugh; AM Goodacre; R Katz; Maria A Rodriguez; D Hill; Fernando Cabanillas; Michael Andreeff
Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma.
Genes, chromosomes & cancer 1994;9(3):161-7.
1994: Anas Younes; Johannes Drach; R Katz; David Jendiroba; M H Sabourian; Andreas H Sarris; F Swan; D Hill; Fernando Cabanillas; R Ford
Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):265-8.
1994: J F Seymour; Anas Younes; Fernando Cabanillas
Lymphomatous presentation of CD4+/CD8+ HTLV-1-related adult T-cell leukemia/lymphoma in an Iranian woman.
Leukemia & lymphoma 1994;12(5-6):471-6.
1994: Jorge Romaguera; Maria A Rodriguez; F B Hagemeister; Peter McLaughlin; F Swan; D F Moore; Andreas H Sarris; Anas Younes; D Hill; Fernando Cabanillas
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Investigational new drugs 1994;12(3):217-22.
1994: Peter McLaughlin; F B Hagemeister; F Swan; Fernando Cabanillas; Jorge Romaguera; Maria A Rodriguez; M S Lee; O Pate; Andreas H Sarris; Anas Younes
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 2():73-7.